Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delafloxacin PK in Hepatic Impairment
NCT02245243Phase 1Completed
- Sponsor
- Melinta Therapeutics
- Start
- Sep 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of delafloxacin in bacterial infection, sponsored by Melinta Therapeutics. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 5 more. Started Sep 2014; status: completed.
02
Drugs
delafloxacin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02245243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245243.